



Tecfidera® (dimethyl fumarate) – First-time generic approval

- On August 19, 2020, [Mylan launched](#) an [AB-rated](#) generic version of Biogen's [Tecfidera \(dimethyl fumarate\)](#) delayed-release capsules.
- Tecfidera is approved for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
- Mylan's generic Tecfidera is the first oral dosage form to receive generic approval for MS.
- According to IQVIA, U.S. sales for Tecfidera for the 12 months ending June 30, 2020 were approximately \$3.79 billion.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.